Product Description

CJC-1295 without DAC

Product Overview

CJC-1295 without DAC is commonly marketed as a modified growth hormone-releasing hormone (GHRH) analogue without the Drug Affinity Complex (DAC) modification. It is frequently associated with Mod GRF (1-29), a modified peptide fragment based on the first 29 amino acids of GHRH. Because commercial naming can vary, the exact amino acid sequence and chemical modifications of the product should be confirmed through supplier documentation.

GHRH is involved in regulating growth hormone release from the anterior pituitary gland. Research on GHRH analogues examines receptor activation, hormone secretion, and the physiological feedback mechanisms that influence the growth hormone and insulin-like growth factor 1 (IGF-1) pathways.

Unlike CJC-1295 with DAC, a peptide without the DAC modification does not have the same albumin-binding feature designed to extend its circulation time. This distinction is relevant to research examining peptide pharmacokinetics, duration of activity, and structure–activity relationships. Evidence specifically establishing the clinical effects and long-term safety of commercially marketed CJC-1295 without DAC remains limited.

Key Research Areas

Growth hormone-releasing hormone receptor signaling

Pituitary growth hormone secretion and endocrine regulation

Growth hormone and IGF-1 pathway investigations

Pharmacokinetics and structure–activity relationships of modified GHRH peptides

Hormonal feedback mechanisms in endocrine research models

Peptide identity, molecular characterization, and analytical verification

Handling & Reconstitution

For laboratory use, reconstitute with Bacteriostatic Water (BAC) or sterile saline. After reconstitution, the solution should be stored at 2–8°C (36–46°F) and used within the appropriate experimental window to maintain peptide stability.